Artificial tears drug is used for the treatment of dry eye syndrome and allergic conjunctivitis. OTC artificial tears help to maintain moisture and well-being mostly in geriatric patients, who are vulnerable to dry eye syndrome due to intake of many medications and dysfunctions of lacrimal gland. This study comprises products only and not the services. The study estimates the revenue generated from the sales of OTC artificial tears. The valuations comprise revenue generated from adoption of OTC artificial tears by patients. The study scope focuses on OTC artificial drugs for hospital pharmacies, drug stores, and online pharmacies.

The increasing applications and benefits of confocal microscope and increasing adoption of confocal microscope is growing in biology, life science, material science, neuroanatomy, and neurophysiology, which is consequently expected to drive the growth of the market for confocal microscope over the forecast period. Rarely diagnosis and treatment of cases of microbial keratitis and along with clinical practices, confocal microscopy is developing into a powerful research and diagnostic tool in ophthalmology is further expected to spur the growth of the market for confocal microscope in the near future

The global surgical instrument tracking devices market is expected to grow at a CAGR of 9.16% for the forecast period 2021-2031. Leading market players strive to retain a competitive edge by having a good presence in key markets and offering a diverse product range. The market has witnessed a total of 32 key developments over the five years (January 2016-March 2021), with a majority of them being product offerings and upgradation accompanied by partnerships, alliances, and business expansions. Efforts are being made to bring more technologically innovative goods to market, each aimed at a particular unmet need. With the launch of new and updated devices with improved features, surgical instrument tracking devices technology has become increasingly possible to unlock new use cases.

The recent technological advancement in the field of next-generation sequencing (NGS) and cell and molecular biology has given birth to the new era of precision medicine, which offers a platform to analyze the variability in genes, lifestyle, and environment of each person individually. Now, the researchers have found an even better option through cell sequencing, which precedes the advancements of next-generation sequencing. In the past few decades, whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) methods have been applied to single cells to combine DNA, RNA, protein, and chromatin information through a single cell. The transcriptomics technique has enabled researchers to use genomics, proteomics, transcriptomics, and epigenomics to understand the heterogeneity of genetically identical cells in the same tissue. The paradigm-shift from bulk cell sequencing to DR-seq (DNA and mRNA sequencing) and G&T-seq (genome and transcriptome), scM&T-seq (simultaneous single-cell methylome and transcriptome sequencing), scNMTseq (single-cell nucleosome, methylation, and transcription sequencing) enable to broaden the understanding of genotypic and phenotypic heterogeneity by using multi-omics approach. Information from different omics platforms can be integrated through this approach, making available deep insights on the effect of these omics’ layers on the underlying mechanisms of disease processes.

The research service will provide an overview of the global wound care solutions market, the competitive landscape, impact of COVID-19, and others. The geographical scope of this global study will be focused on three key regions namely, North America (NA), Europe, Asia-Pacific (APAC) and Rest of world (RoW). This study will provide a six-year global market revenue forecast from 2021 to 2026. This research service will offer a detailed segment analysis of the advanced wound care solutions, including the various next-generation solutions that are set to dominate the market. It will not cover basic and surgical wound care solutions. Wound care products related to pharmaceuticals and life sciences are also excluded from the study scope. The forecast for this study covers the wound care continuum approach comprising wound prevention and diagnosis solutions and wound management solutions.

The prevalence of several chronic diseases worldwide and the launch of sophisticated technologies and treatments have contributed to a rapid increase in healthcare expenses. Additionally, patients nowadays expect high-quality care at an affordable cost. Thus, it has become imperative for players in the healthcare industry to reduce the cost of their healthcare services while providing high-quality care to patients. Efficient healthcare logistics services provide a remarkable opportunity for controlling healthcare costs through the implementation of best practices. Moreover, the need for an effective flow of materials and information has been evident throughout history. In the healthcare business, materials and goods are always on the move. Hospitals and healthcare centers have huge central warehouses, small parts storage units, and everything in between. In healthcare warehousing, the biggest challenges entail supervising products with due dates, optimizing item titles, and enhancing processes while ordering supplies. Proper inventory management and the smooth movement of necessary healthcare products within the hospital premises may result in considerable savings instead of frequent new product orders.

The CRO market comprises services segmented into nonclinical and clinical based on the drug development stage. Some services, such as bioanalytical services, are peripheral services spanning both nonclinical and clinical drug development stages. This study focuses only on the broad core services in the CRO industry. The nonclinical segment includes drug discovery services and preclinical services. Further subsegments are not included in this study.

生物制药上游行业技术壁垒高，客户粘性强。生物制药上游行业包括下游科研、研发、生产所需的仪器、设备、原料和耗材，涉及物理、材料、电子、生物等多学科交叉，该行业产品种类丰富，研发难度大，技术壁垒高。产品注册制度导致下游用户更换核心原料、生产设备的成本高、代价大，因此客户对上游供应商选择谨慎，用户粘性强，行业护城河宽。

硬镜用于微创外科手术的术中成像，微创手术已成为多类疾病的金标准术式，微创手术的繁荣不断丰富内窥镜的种类，应用场景多元化。技术和术式创新，书写百年硬镜诊疗史，内窥镜的发展促进微创手术的发展，同时微创手术的进步对内窥镜提出了更高的要求，相互促进、正向循环。

日内瓦药品专利池(MPP)组织宣布，已与27 家仿制药企业签署协议，生产默克口服COVID-19 抗病毒药物molnupiravir，并向105 个低收入和中等收入国家供应。中国药企中，博瑞医药、复星医药、迪赛诺、龙泽制药、朗华制药（维亚生物）5 家入选。